Schematic Diagram & Description

The URB937 drug is excluded from the brain by a transporter with a pharmacology resembling BCRP, but is free to act on peripheral FAAH. The site of analgesic action is most likely peripheral pain-sensing nerve endings (red circle). Expanded red circle shows the predicted molecular mechanism of drug action, inhibition of FAAH-catalyzed metabolism of anandamide (AEA), which allows for persistent AEA activation of peripheral CB1 receptors on peripheral nerve endings. Activation of CB1 receptors ultimately reduces transmission of pain signals to the spinal cord, preventing pain sensation (Modified from Nature Neuroscience).

A transformative therapy for non-addictive management of chronic and acute pain

Based on preclinical efficacy data, mechanism of action and a significant unmet medical need, Exxel Pharma is developing URB937 as a transformative therapy for non-addictive management of chronic neuropathic pain. The clinical lead indication is Chronic Neuropathic Pain of Peripheral Neuropathy, representing a market that has been estimated to reach $3.6 billion by 2020 (Nature Reviews), and which is ripe for disruption by novel, safe, non-addictive therapies such as URB937.

Key Scientific URB937 Publications

A list of published, peer-reviewed URB937 studies, including work from international, academic research laboratories, can be found here.

For more information, please contact us.